Related Experiment Video

Updated: May 20, 2025

Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.
09:21

Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.

Published on: February 15, 2019

10.5K

Lanostane-Type Triterpenes From Poria cocos Peels and Their α-Glucosidase Inhibitory Activity

Yu-Yu Xu1, Xiao-Yue Wang1, Yi Xu1

  • 1College of Food Science & Engineering, Northwest University, Xi'an, China.

Chemistry & Biodiversity
|March 23, 2025
PubMed
Abstract

Keywords:
Poria cocosedible mushroomlanostane‐type triterpenesα‐glucosidase inhibitory

More Related Videos

Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks09:18

Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks

Published on: December 2, 2022

1.0K
Author Spotlight: Integrating Biochemical Functions of β-Glucanases and Peroxidase Enzymes in Wheat-RWA Interaction10:26

Author Spotlight: Integrating Biochemical Functions of β-Glucanases and Peroxidase Enzymes in Wheat-RWA Interaction

Published on: July 26, 2024

566

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
134
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277